G-NiiB Liver Goal Formula (SLD07)

Overview

Developed by CUHK Faculty of Medicine, Liver Goal Formula (SLD07) is a novel synbiotic targeting the gut microbiome. Formulated using faecal metagenomics and clinical data, it combines specific probiotics and prebiotics. By regulating liver metabolism, it aims to reduce severe liver fat problem (MAFLD) and repair liver scars. Clinical study proved that liver fat score and liver stiffness score significantly reduced. The formula has been enhanced with vitamin E for superior antioxidant liver protection.

  • G-NiiB Liver Goal Formula (SLD07)
Commercialisation opportunities
G-NiiB Liver Goal formula is now commercially available in Hong Kong and China.
Problem addressed

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a common metabolic liver disorder, and its prevalence continues to rise with obesity, insulin resistance, and unhealthy dietary habits, creating a significant medical and social burden. Its key features include abnormal lipid accumulation in liver cells, liver inflammation, oxidative stress, and an increased risk of fibrosis; as the disease progresses, it may develop into steatohepatitis, cirrhosis, or even liver cancer. At present, there is no single drug that can completely cure it, and there remains a major unmet need for effective therapies targeting metabolic dysfunction, dysregulation of the gut-liver axis, and related inflammatory mechanisms. Early detection and intervention are crucial for reversing disease progression.

Innovation
  • Scientifically formulated using CUHK’s proprietary faecal metagenomics and clinical data, targeting specific microbiome dysbiosis observed in severe liver fat patients.
  • Unique blend of 5 probiotic species (Lactobacillus and Bifidobacterium) and 4 prebiotics.
  • Specifically designed to modulate the gut-liver axis, regulating liver metabolism, significantly reduces severe liver fat and significantly repairs liver scars.
Key impact
  • Clinical study (n=27) demonstrated significant reduction in liver fat score and liver stiffness score in severe liver fat patients.
  • Regulates liver metabolism and enhances anti-inflammatory factors via the gut-liver axis.
  • Offers a novel and safe therapeutic strategy targeting a key modifiable environmental factor, the gut microbiome, in fatty liver conditions.
  • Potential for broad application beyond fatty liver conditions to enhance overall liver health.
Award
  • 51th International Exhibition of Inventions Geneva - Gold Medal
  • 51th International Exhibition of Inventions Geneva - Saudi Innovation Excellence Prize – Ministry of Health
Application
  • Through modulating the gut-liver axis, regulates liver metabolism, significantly reduces severe liver fat score and liver stiffness score.
  • Broad application beyond fatty liver conditions to enhance overall liver health.
The Chinese University of Hong Kong (CUHK)

Founded in 1963, The Chinese University of Hong Kong (CUHK) is a forward-looking comprehensive research university with a global vision and a mission to combine tradition with modernity, and to bring together China and the West. CUHK teachers and students hail from all around the world. Four Nobel laureates are associated with the university, and it is the only tertiary institution in Hong Kong with recipients of the Nobel Prize, Turing Award, Fields Medal and Veblen Prize sitting as faculty in residence. CUHK graduates are connected worldwide through an extensive alumni network. CUHK undertakes a wide range of research programmes in many subject areas, and strives to provide scope for all academic staff to undertake consultancy and collaborative projects with industry. 

Enquiry
Related Innovations